RNA Editing at Baseline and Following Endoplasmic Reticulum Stress

Total Page:16

File Type:pdf, Size:1020Kb

RNA Editing at Baseline and Following Endoplasmic Reticulum Stress RNA Editing at Baseline and Following Endoplasmic Reticulum Stress By Allison Leigh Richards A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Human Genetics) in The University of Michigan 2015 Doctoral Committee: Professor Vivian G. Cheung, Chair Assistant Professor Santhi K. Ganesh Professor David Ginsburg Professor Daniel J. Klionsky Dedication To my father, mother, and Matt without whom I would never have made it ii Acknowledgements Thank you first and foremost to my dissertation mentor, Dr. Vivian Cheung. I have learned so much from you over the past several years including presentation skills such as never sighing and never saying “as you can see…” You have taught me how to think outside the box and how to create and explain my story to others. I would not be where I am today without your help and guidance. Thank you to the members of my dissertation committee (Drs. Santhi Ganesh, David Ginsburg and Daniel Klionsky) for all of your advice and support. I would also like to thank the entire Human Genetics Program, and especially JoAnn Sekiguchi and Karen Grahl, for welcoming me to the University of Michigan and making my transition so much easier. Thank you to Michael Boehnke and the Genome Science Training Program for supporting my work. A very special thank you to all of the members of the Cheung lab, past and present. Thank you to Xiaorong Wang for all of your help from the bench to advice on my career. Thank you to Zhengwei Zhu who has helped me immensely throughout my thesis even through my panic. Thank you to Jonathan Toung who taught me how to code and was so patient when I had trouble. Thank you to Alan Bruzel who helped me with protocols and made my whole experience more enjoyable. And thank you to everyone else in the Cheung lab for all of your fun and support. iii I would especially like to thank my friends who not only helped me with my lab work but also kept me sane: Michelle Nguyen-McCarty, Lauren Brady, Jillian Boden and Becky Glineburg. Michelle, thank you for the support and the distractions. Becky, thank you for introducing me to fun; it has served me well. Lauren, thank you for the understanding and the gossip. Jill, thank you for the lunches and steadying me when I get off-balance. And finally, I would like to thank my family. To my father for always believing in me and comforting me when all seemed lost. To my mother who always listened even when I repeated myself 20 times. Thank you to Deborah and Ted for your support. And thank you to Matt, who never let me give up. Without even one of you, I could never have accomplished anything. iv Table of Contents Dedication.......................................................................................................................................ii Acknowledgments…………………………………………………………………………………………………………………….iii List of Figures…………………………………………………………………………………………………………………………….ix List of Tables…………………………………………………………………………………………………………………………….x Abstract…………………………………………………………………………………………………………………………………….xi Chapter 1: Introduction………………………………………………………………………………………………………..……1 Identification of RNA Editing…………………………………………………………………………………………..2 RNA Editing in Plants………………………………………………………………………………………………………4 Identification of RNA Editing in Mammals………………………………………………………………………5 ADAR RNA Editing…………………………………………………………………………………………………………..7 Non-canonical Editing…………………………………………………………………………………………………..11 Endoplasmic Reticulum Stress………………………………………………………………………………………12 My Thesis Summary……………………………………………………………………………………………………..14 References……………………………………………………………………………………………………………………15 Chapter 2: Widespread RNA and DNA Sequence Differences in the Human Transcriptome…….26 Abstract……………………………………………………………………………………………………………………….26 Introduction…………………………………………………………………………………………………………………27 Samples………………………………………………………………………………………………………………………..28 Differences between RNA and corresponding DNA sequences………….……………………….30 RDD in expressed sequence tags………………………………………………………………………………..32 Sanger sequencing of B cells, skin, and brain………………………………………………………………..33 Proteomic evidence of RDD………………………………………………………………………………………….34 v Individual variation in abundance of RDD…………………………………………………………………..36 Characteristics of RDD sites………………………………………………………………………………………….37 RDD levels…………………………………………………………………………………………………………………….38 Conclusions………………………………………………………………………………………………………………….39 References……………………………………………………………………………………………………………………41 Tables and Figures………………………………………………………………………………………………………..46 Chapter 3: RNA-DNA Differences Are Generated in Human Cells within Seconds After RNA Exits Pol II…………………………………………………………………………………………………………………………………………52 Abstract……………………………………………………………………………………………………………………….52 Introduction…………………………………………………………………………………………………………………53 Nascent RNA from GRO-seq and PRO-seq…………………………………………………………………….55 RDDs in very nascent RNA…………………………………………………………………………………………….56 RDD formation occurs within seconds after transcription…………………………………………….59 RDD frequency is lower in cells from a patient with Senataxin mutation………………………61 A-to-G RDDs in very nascent RNA are not mediated by ADAR…………………………………..….62 Other characteristics of RDDs in very nascent RNA…………………………………………………....63 Conclusions………………………………………………………………………………………………………………….64 Experimental Procedures……………………………………………………………………………………………..66 References……………………………………………………………………………………………………………………70 Tables and Figures………………………………………………………………………………………………………..75 Chapter 4: Cis Regulation of RNA Editing in Human………………………………………………………………….82 Abstract……………………………………………………………………………………………………………………….82 Introduction…………………………………………………………………………………………………………………83 Identification of RNA editing and RDDs in human B-cells………………………..…………………...84 vi Characteristics of RNA editing and RDD………………………………………………………………………..85 Cis-Regulation of RNA editing levels……………………………………………………………………………..86 Individual variation in RNA editing levels………………………………………………………………………88 Effect of genomic variation on RNA editing………………………………………..………………………..89 SEC16A…………………………………………………………………………………………………………………………89 Conclusions…………………………………………………………………………………………………………………92 Methods……………………………………………………………………………………………………………………….93 References…………………………………………………………………………………………………………………100 Tables and Figures………………………………………………………………………………………………………102 Chapter 5: RNA Editing in Response to ER Stress in Human B-cells……………………………….……….122 Abstract……………………………………………………………………………………………………………………..122 Introduction……………………………………………………………………………………………………………….123 Induction of ER stress…………………………………………………………………………………………………124 Gene expression changes following ER stress…………………………………………………………….124 ADAR RNA editing levels following ER stress……………………………………….……..………………126 Validation of ADAR editing following ER stress……………………………………………………………128 ADAR editing and gene expression……………………………………………………………………………..129 Conclusions………………………………………………………………………………………………………………..131 Methods…………………………………………………………………………………………………………………….132 References………………………………………………………………………………………………………………….138 Tables and Figures………………………………………………………………………………………………………140 Chapter 6: Conclusion…………………………………………………………………………………………………………….146 Summary of Findings……………………………………………..…………………………………………………..146 vii Significance………………………………………………………………………………………………………………..148 On-going Work……………………………………………………………………………………………………………149 Future Directions………………………………………………………………………………………………………..151 In Summary………………………………………………………………………………………………………………..153 Methods…………………………………………………………………………………………………………………….154 References………………………………………………………………………………………………………………….155 Tables and Figures………………………………………………………………………………………………………160 viii List of Figures Figure 2.1: Characteristics of RDD sites……………………………………………………………………………………50 Figure 2.2: Identification of peptides coded by both RNA and DNA sequences………………………..51 Figure 3.1: GRO-seq and PRO-seq analysis……………………………………………………………………………….78 Figure 3.2: Analysis steps to identify RNA-DNA sequence differences………………………………………79 Figure 3.3: RNA-DNA differences in very nascent transcripts……………………………………………………80 Figure 3.4: Locations of RDD sites within sequence reads………………………………………………………..81 Figure 4.1: Characteristics of RNA editing sites and RDDs………………………………………………………102 Figure 4.2: Correlation of editing levels of sites in the same transcript…………………………………..103 Figure 4.3: Cis-association of editing levels…………………………………………………………………………….104 Figure 4.4: RNA Editing of SEC16A………………………………………………………………………………………….105 Figure S4.1: Analysis for identification of RDDs among ten individuals…………………………………..117 Figure S4.2: ATG14: Example of RNA folding and editing…………………………..…………………………..118 Figure S4.3: Editing of SEC16A in three tissues……………………………………………………………………….119 Figure S4.4: HuR RNA-IP of SEC16A……………………………………………………..…………………………………120 Figure S4.5: HuR RNA-IP by ddPCR……………………………………………………………..………………………….121 Figure 5.1: Gene expression changes following ER stress…………………………………..…………………..140 Figure 5.2: Editing level changes following ER stress……………………………..……………………………….141 Figure 5.3: Editing level and gene expression following ER stress…………………………………………..142 Figure S5.1: ADAR expression under ER stress conditions…………………………..………………………….145 Figure 6.1: Effect of HuR and ADAR knock-down on editing of SEC16A…………………..……………..160 ix List of Tables Table 2.1: Selected examples of sites that show RNA-DNA Differences in B-cells and EST clones………………………………………………………………………………………………………………………………………46 Table 2.2: Sanger sequencing of RDD sites……………………………………………………………………………….47 Table 2.3: Peptides encoded
Recommended publications
  • Supplementary Data
    Figure 2S 4 7 A - C 080125 CSCs 080418 CSCs - + IFN-a 48 h + IFN-a 48 h + IFN-a 72 h 6 + IFN-a 72 h 3 5 MRFI 4 2 3 2 1 1 0 0 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 7 B 13 080125 FBS - D 080418 FBS - + IFN-a 48 h 12 + IFN-a 48 h + IFN-a 72 h + IFN-a 72 h 6 080125 FBS 11 10 5 9 8 4 7 6 3 MRFI 5 4 2 3 2 1 1 0 0 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 Molecule Molecule FIGURE 4S FIGURE 5S Panel A Panel B FIGURE 6S A B C D Supplemental Results Table 1S. Modulation by IFN-α of APM in GBM CSC and FBS tumor cell lines. Molecule * Cell line IFN-α‡ HLA β2-m# HLA LMP TAP1 TAP2 class II A A HC§ 2 7 10 080125 CSCs - 1∞ (1) 3 (65) 2 (91) 1 (2) 6 (47) 2 (61) 1 (3) 1 (2) 1 (3) + 2 (81) 11 (80) 13 (99) 1 (3) 8 (88) 4 (91) 1 (2) 1 (3) 2 (68) 080125 FBS - 2 (81) 4 (63) 4 (83) 1 (3) 6 (80) 3 (67) 2 (86) 1 (3) 2 (75) + 2 (99) 14 (90) 7 (97) 5 (75) 7 (100) 6 (98) 2 (90) 1 (4) 3 (87) 080418 CSCs - 2 (51) 1 (1) 1 (3) 2 (47) 2 (83) 2 (54) 1 (4) 1 (2) 1 (3) + 2 (81) 3 (76) 5 (75) 2 (50) 2 (83) 3 (71) 1 (3) 2 (87) 1 (2) 080418 FBS - 1 (3) 3 (70) 2 (88) 1 (4) 3 (87) 2 (76) 1 (3) 1 (3) 1 (2) + 2 (78) 7 (98) 5 (99) 2 (94) 5 (100) 3 (100) 1 (4) 2 (100) 1 (2) 070104 CSCs - 1 (2) 1 (3) 1 (3) 2 (78) 1 (3) 1 (2) 1 (3) 1 (3) 1 (2) + 2 (98) 8 (100) 10 (88) 4 (89) 3 (98) 3 (94) 1 (4) 2 (86) 2 (79) * expression of APM molecules was evaluated by intracellular staining and cytofluorimetric analysis; ‡ cells were treatead or not (+/-) for 72 h with 1000 IU/ml of IFN-α; # β-2 microglobulin; § β-2 microglobulin-free HLA-A heavy chain; ∞ values are indicated as ratio between the mean of fluorescence intensity of cells stained with the selected mAb and that of the negative control; bold values indicate significant MRFI (≥ 2).
    [Show full text]
  • Global Characteristics of Csig-Associated Gene Expression Changes in Human Hek293 Cells and the Implications for Csig Regulating Cell Proliferation and Senescence
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector ORIGINAL RESEARCH published: 15 May 2015 doi: 10.3389/fendo.2015.00069 Global characteristics of CSIG-associated gene expression changes in human HEK293 cells and the implications for CSIG regulating cell proliferation and senescence Liwei Ma, Wenting Zhao, Feng Zhu, Fuwen Yuan, Nan Xie, Tingting Li, Pingzhang Wang and Tanjun Tong* Research Center on Aging. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Edited by: Beijing, China Wen Zhou, Columbia University, USA Reviewed by: Cellular senescence-inhibited gene (CSIG), also named as ribosomal_L1 domain-contain- Jian Zhong, ing 1 (RSL1D1), is implicated in various processes including cell cycle regulation, cellular Mayo Clinic, USA Xiaoxu Zheng, senescence, apoptosis, and tumor metastasis. However, little is known about the regulatory University of Maryland Baltimore, USA mechanism underlying its functions. To screen important targets and signaling pathways Wensi Tao, University of Miami, USA modulated by CSIG, we compared the gene expression profiles in CSIG-silencing and control *Correspondence: HEK293 cells using Affymetrix microarray Human Genome U133 Plus 2.0 GeneChips. A Tanjun Tong, total of 590 genes displayed statistically significant expression changes, with 279 genes Department of Biochemistry and up-regulated and 311 down-regulated, respectively. These genes are involved in a broad array Molecular Biology, Research Center on Aging, Peking University Health of biological processes, mainly in transcriptional regulation, cell cycle, signal transduction, Science Center, 38 Xueyuan Road, oxidation reduction, development, and cell adhesion.
    [Show full text]
  • IP6K1 Upregulates the Formation of Processing Bodies by Promoting Proteome Remodeling on the Mrna Cap
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.13.199828; this version posted July 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. IP6K1 upregulates the formation of processing bodies by promoting proteome remodeling on the mRNA cap Akruti Shah1,2 and Rashna Bhandari1* 1Laboratory of Cell Signalling, Centre for DNA Fingerprinting and Diagnostics (CDFD), Inner Ring Road, Uppal, Hyderabad 500039, India. 2Graduate studies, Manipal Academy of Higher Education, Manipal 576104, India. *Correspondence to Rashna Bhandari; Email: [email protected] Running title: IP6K1 promotes mRNA turnover to induce P-bodies ORCID IDs Akruti Shah - 0000-0001-9557-4952 Rashna Bhandari - 0000-0003-3101-0204 This PDF file includes: Main Text Figures 1 to 6 Keywords mRNA decay/mRNA metabolism/P-bodies/translation suppression 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.13.199828; this version posted July 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Inositol hexakisphosphate kinases (IP6Ks) are ubiquitously expressed small molecule kinases that catalyze the conversion of the inositol phosphate IP6 to 5-IP7. IP6Ks have been reported to influence cellular functions by protein-protein interactions independent of their enzymatic activity.
    [Show full text]
  • Genomic Alterations of Ground-Glass Nodular Lung Adenocarcinoma
    www.nature.com/scientificreports OPEN Genomic alterations of ground- glass nodular lung adenocarcinoma Hyun Lee1, Je-Gun Joung2, Hyun-Tae Shin2, Duk-Hwan Kim3, Yujin Kim3, Hojoong Kim1, O. Jung Kwon1, Young Mog Shim4, Ho Yun Lee5, Kyung Soo Lee5, Yoon-La Choi6, 2 7 1 Received: 1 February 2018 Woong-Yang Park , D. Neil Hayes & Sang-Won Um Accepted: 30 April 2018 In-depth molecular pathogenesis of ground-glass nodular lung adenocarcinoma has not been well Published: xx xx xxxx understood. The objectives of this study were to identify genomic alterations in ground-glass nodular lung adenocarcinomas and to investigate whether viral transcripts were detected in these tumors. Nine patients with pure (n = 4) and part-solid (n = 5) ground-glass nodular adenocarcinomas were included. Six were females with a median age of 58 years. We performed targeted exon sequencing and RNA sequencing. EGFR (n = 10), IDH2 (n = 2), TP53 (n = 1), PTEN (n = 1), EPHB4 (n = 1), and BRAF (n = 1) were identifed as driver mutations by targeted exon sequencing. Vasculogenesis-associated genes including NOTCH4 and TGFBR3 expression were signifcantly downregulated in adenocarcinoma tissue versus normal tissue (adjusted P values < 0.001 for both NOTCH4 and TGFBR3). In addition, fve novel fusion gene loci were identifed in four lung adenocarcinomas. However, no signifcant virus-associated transcripts were detected in tumors. In conclusions, EGFR, IDH2, TP53, PTEN, EPHB4, and BRAF were identifed as putative driver mutations of ground-glass nodular adenocarcinomas. Five novel fusion genes were also identifed in four tumors. Viruses do not appear to be involved in the tumorigenesis of ground-glass nodular lung adenocarcinoma.
    [Show full text]
  • HOOK3 Is a Scaffold for the Opposite-Polarity Microtubule-Based
    bioRxiv preprint doi: https://doi.org/10.1101/508887; this version posted December 31, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. HOOK3 is a scaffold for the opposite-polarity microtubule-based motors cytoplasmic dynein and KIF1C Agnieszka A. Kendrick1, William B. Redwine1,2†, Phuoc Tien Tran1‡, Laura Pontano Vaites2, Monika Dzieciatkowska4, J. Wade Harper2, and Samara L. Reck-Peterson1,3,5 1Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, 92093. 2 Department of Cell Biology, Harvard Medical School, Boston, MA 02115. 3Section of Cell and Developmental Biology, Division of Biological Sciences, University of California San Diego, La Jolla, CA 92093. 4Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, CO 80045. 5Howard Hughes Medical Institute †Present address: Stowers Institute for Medical Research, Kansas City, MO 64110 ‡Present address: Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138. *Correspondence to: Samara Reck-Peterson 9500 Gilman Drive, Leichtag 482 La Jolla CA, 92093 [email protected]; https://orcid.org/0000-0002-1553-465X 1 bioRxiv preprint doi: https://doi.org/10.1101/508887; this version posted December 31, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]
  • Product Datasheet KIF1C Antibody NB100-57510
    Product Datasheet KIF1C Antibody NB100-57510 Unit Size: 0.1 ml Store at 4C. Do not freeze. Reviews: 1 Publications: 1 Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB100-57510 Updated 3/16/2021 v.20.1 Earn rewards for product reviews and publications. Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB100-57510 Page 1 of 3 v.20.1 Updated 3/16/2021 NB100-57510 KIF1C Antibody Product Information Unit Size 0.1 ml Concentration 0.2 mg/ml Storage Store at 4C. Do not freeze. Clonality Polyclonal Preservative 0.09% Sodium Azide Isotype IgG Purity Immunogen affinity purified Buffer TBS and 0.1% BSA Product Description Host Rabbit Gene ID 10749 Gene Symbol KIF1C Species Human, Mouse Immunogen The immunogen recognized by this antibody maps to a region between residue 1053 and the C-terminus (residue 1103) of human kinesin family member 1C (lethal toxin sensitivity 1) using the numbering given in entry NP_006603.2 (GeneID 10749). Product Application Details Applications Western Blot, Immunoprecipitation Recommended Dilutions Western Blot 1:2000-1:10000, Immunoprecipitation 2 - 5 ug/mg lysate Page 2 of 3 v.20.1 Updated 3/16/2021 Images Western Blot: KIF1C Antibody [NB100-57510] - KIF1C is a novel HOOK3 -interacting protein.sfGFP-3xFLAG and full length (FL) HOOK3, HOOK3 (1-552), and HOOK3 (553-718) all tagged with sfGFP and 3xFLAG were immunoprecipitated with alpha-FLAG antibodies from transiently transfected HEK-293T cells. Western blots with alpha-HC, alpha- FAM160A2, alpha-KIF1C, and alpha-FLAG antibodies were used to determine which proteins co-immunoprecipitated with each HOOK3 construct.DOI:http://dx.doi.org/10.7554/eLife.28257.015 Image collected and cropped by CiteAb from the following publication (https://elifesciences.org/articles/28257), licensed under a CC-BY licence.
    [Show full text]
  • 047605V1.Full.Pdf
    bioRxiv preprint doi: https://doi.org/10.1101/047605; this version posted April 8, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Assembly and Activation of Dynein-Dynactin by the Cargo Adaptor Protein Hook3 Courtney M. Schroeder1,2 and Ronald D. Vale1,2 1The Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, California, USA 2Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California, USA. Corresponding Author: Ronald D. Vale Dept. of Cellular and Molecular Pharmacology University of California, San Francisco Genentech Hall, MC 2200, Room N312A 600-16th Street San Francisco, CA 94158-2517 E-mail: [email protected] Phone: 415-476-6380 Fax: 415-514-4412 bioRxiv preprint doi: https://doi.org/10.1101/047605; this version posted April 8, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 2 Abstract Metazoan cytoplasmic dynein moves processively along microtubules with the aid of dynactin and an adaptor protein that joins dynein and dynactin into a stable ternary complex. Here, we have examined how Hook3, a cargo adaptor involved in Golgi and endosome transport, forms a motile dynein-dynactin complex. We show that the conserved Hook domain interacts directly with the dynein light intermediate chain 1 (LIC1).
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Anti-DFNA5 Antibody (Internal) Rabbit Anti Human Polyclonal Antibody Catalog # ALS17405
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Anti-DFNA5 Antibody (Internal) Rabbit Anti Human Polyclonal Antibody Catalog # ALS17405 Specification Anti-DFNA5 Antibody (Internal) - Product Information Application WB, IHC-P Primary Accession O60443 Predicted Human, Mouse, Rat Host Rabbit Clonality Polyclonal Calculated MW 54555 Anti-DFNA5 Antibody (Internal) - Additional Information Gene ID 1687 Alias Symbol DFNA5 Other Names DFNA5, ICERE-1, Deafness, autosomal dominant 5, ICERE1 Target/Specificity Recognizes endogenous levels of DFNA5 protein. Reconstitution & Storage PBS, pH 7.3, 0.01% sodium azide, 30% glycerol. Store at -20°C. Aliquot to avoid freeze/thaw cycles. Precautions Anti-DFNA5 Antibody (Internal) is for research use only and not for use in diagnostic or therapeutic procedures. Anti-DFNA5 Antibody (Internal) - Protein Information Name GSDME {ECO:0000303|PubMed:28459430, ECO:0000312|HGNC:HGNC:2810} Function [Gasdermin-E]: Precursor of a pore-forming protein that converts non-inflammatory apoptosis to pyroptosis (PubMed:<a href=" Page 1/2 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 http://www.uniprot.org/citations/27281216" target="_blank">27281216</a>, PubMed:<a href="http://www.uniprot.org/ci tations/28459430" target="_blank">28459430</a>). This form constitutes the precursor of the pore- forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed:<a hr ef="http://www.uniprot.org/citations/28459 430" target="_blank">28459430</a>). Cellular Location [Gasdermin-E, N-terminal]: Cell membrane; Multi-pass membrane protein {ECO:0000250|UniProtKB:Q5Y4Y6} Tissue Location Expressed in cochlea (PubMed:9771715).
    [Show full text]
  • Investigation of RNA-Mediated Pathogenic Pathways in a Drosophila Model of Expanded Repeat Disease
    Investigation of RNA-mediated pathogenic pathways in a Drosophila model of expanded repeat disease A thesis submitted for the degree of Doctor of Philosophy, June 2010 Clare Louise van Eyk, B.Sc. (Hons.) School of Molecular and Biomedical Science, Discipline of Genetics The University of Adelaide II Table of Contents Index of Figures and Tables……………………………………………………………..VII Declaration………………………………………………………………………………......XI Acknowledgements…………………………………………………………………........XIII Abbreviations……………………………………………………………………………....XV Drosophila nomenclature…………………………………………………………….….XV Abstract………………………………………………………………………………........XIX Chapter 1: Introduction ............................................................................................1 1.0 Expanded repeat diseases....................................................................................1 1.1 Translated repeat diseases...................................................................................2 1.1.1 Polyglutamine diseases .............................................................................2 Huntington’s disease...................................................................................3 Spinal bulbar muscular atrophy (SBMA) .....................................................3 Dentatorubral-pallidoluysian atrophy (DRPLA) ...........................................4 The spinal cerebellar ataxias (SCAs)..........................................................4 1.1.2 Pathogenesis and aggregate formation .....................................................7
    [Show full text]
  • The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid
    The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome Annette K. Brenner, Elise Aasebø, Maria Hernandez-Valladares, Frode Selheim, Frode Berven, Ida-Sofie Grønningsæter, Sushma Bartaula-Brevik and Øystein Bruserud Supplementary Material S2 of S31 Table S1. Detailed information about the 68 AML patients included in the study. # of blasts Viability Proliferation Cytokine Viable cells Change in ID Gender Age Etiology FAB Cytogenetics Mutations CD34 Colonies (109/L) (%) 48 h (cpm) secretion (106) 5 weeks phenotype 1 M 42 de novo 241 M2 normal Flt3 pos 31.0 3848 low 0.24 7 yes 2 M 82 MF 12.4 M2 t(9;22) wt pos 81.6 74,686 low 1.43 969 yes 3 F 49 CML/relapse 149 M2 complex n.d. pos 26.2 3472 low 0.08 n.d. no 4 M 33 de novo 62.0 M2 normal wt pos 67.5 6206 low 0.08 6.5 no 5 M 71 relapse 91.0 M4 normal NPM1 pos 63.5 21,331 low 0.17 n.d. yes 6 M 83 de novo 109 M1 n.d. wt pos 19.1 8764 low 1.65 693 no 7 F 77 MDS 26.4 M1 normal wt pos 89.4 53,799 high 3.43 2746 no 8 M 46 de novo 26.9 M1 normal NPM1 n.d. n.d. 3472 low 1.56 n.d. no 9 M 68 MF 50.8 M4 normal D835 pos 69.4 1640 low 0.08 n.d.
    [Show full text]
  • Plenary and Platform Abstracts
    American Society of Human Genetics 68th Annual Meeting PLENARY AND PLATFORM ABSTRACTS Abstract #'s Tuesday, October 16, 5:30-6:50 pm: 4. Featured Plenary Abstract Session I Hall C #1-#4 Wednesday, October 17, 9:00-10:00 am, Concurrent Platform Session A: 6. Variant Insights from Large Population Datasets Ballroom 20A #5-#8 7. GWAS in Combined Cancer Phenotypes Ballroom 20BC #9-#12 8. Genome-wide Epigenomics and Non-coding Variants Ballroom 20D #13-#16 9. Clonal Mosaicism in Cancer, Alzheimer's Disease, and Healthy Room 6A #17-#20 Tissue 10. Genetics of Behavioral Traits and Diseases Room 6B #21-#24 11. New Frontiers in Computational Genomics Room 6C #25-#28 12. Bone and Muscle: Identifying Causal Genes Room 6D #29-#32 13. Precision Medicine Initiatives: Outcomes and Lessons Learned Room 6E #33-#36 14. Environmental Exposures in Human Traits Room 6F #37-#40 Wednesday, October 17, 4:15-5:45 pm, Concurrent Platform Session B: 24. Variant Interpretation Practices and Resources Ballroom 20A #41-#46 25. Integrated Variant Analysis in Cancer Genomics Ballroom 20BC #47-#52 26. Gene Discovery and Functional Models of Neurological Disorders Ballroom 20D #53-#58 27. Whole Exome and Whole Genome Associations Room 6A #59-#64 28. Sequencing-based Diagnostics for Newborns and Infants Room 6B #65-#70 29. Omics Studies in Alzheimer's Disease Room 6C #71-#76 30. Cardiac, Valvular, and Vascular Disorders Room 6D #77-#82 31. Natural Selection and Human Phenotypes Room 6E #83-#88 32. Genetics of Cardiometabolic Traits Room 6F #89-#94 Wednesday, October 17, 6:00-7:00 pm, Concurrent Platform Session C: 33.
    [Show full text]